Research graph
References from Nucleolar METTL16 drives ccRCC tumorigenesis and pazopanib resistance via translational activation of JAG1/Notch signaling pathway. Local targets link to admitted publications; unresolved targets remain external evidence.
Metabolomics reveals tyrosine kinase inhibitor resistance-associated metabolic events in human metastatic renal cancer cells
10.3390/ijms25126328 · 2024 · External reference
Methyl-transferase-like protein 16 (METTL16): the intriguing journey of a key epitranscriptomic player becoming an emerging biological target
10.1021/acs.jmedchem.4c01247 · 2024 · External reference
Targeting the translation machinery in cancer
10.1038/nrd4505 · 2015 · External reference
Pazopanib
10.1038/nrd3073 · 2010 · External reference
CDK13 drives clear cell renal carcinoma through METTL16-mediated m6A modification of ACLY mRNA
10.1038/s12276-025-01634-7 · 2026 · External reference
The promoting effect of the POU3F2/METTL16/PFKM cascade on glycolysis and tumorigenesis of hepatocellular carcinoma
10.1016/j.aohep.2025.101776 · 2025 · External reference
iProX in 2021: connecting proteomics data sharing with big data
10.1093/nar/gkab1081 · 2022 · External reference
Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma
10.1038/s41420-023-01423-z · 2023 · External reference
Database resources of the National Genomics Data Center, China National Center for Bioinformation in 2026
10.1093/nar/gkaf1172 · 2026 · External reference
METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m6A-dependent manner
10.1186/s11658-022-00342-8 · 2022 · External reference
Emerging role of eukaryote ribosomes in translational control
10.3390/ijms20051226 · 2019 · External reference
Grading of renal cell carcinoma
10.1111/his.13735 · 2019 · External reference
Proteogenomic characterization of endometrial carcinoma
10.1016/j.cell.2020.01.026 · 2020 · External reference
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
10.1200/jco.2013.50.8267 · 2014 · External reference
Coexisting Liquid Phases Underlie Nucleolar Subcompartments
10.1016/j.cell.2016.04.047 · 2016 · External reference
METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism
10.1016/j.stem.2022.12.006 · 2023 · External reference
Efficacy and safety of Pazopanib in patients with metastatic renal cell carcinoma
10.1200/jco.2008.21.6994 · 2010 · External reference
Renal cancer: signaling pathways and advances in targeted therapies
10.1002/mco2.676 · 2024 · External reference
Epidemiology of renal cancer: incidence, mortality, survival, genetic predisposition, and risk factors
10.1016/j.eururo.2025.06.005 · 2025 · External reference
METTL16 inhibits papillary thyroid cancer tumorigenicity through m6A/YTHDC2/SCD1-regulated lipid metabolism
10.1007/s00018-024-05146-x · 2024 · External reference
GLI2/Parkin-mediated mitophagy promotes pazopanib resistance in clear cell renal cell carcinoma
10.1016/j.cellsig.2025.112054 · 2025 · External reference
A novel cinnamic acid derivative for hepatocellular carcinoma therapy by degrading METTL16 protein
10.1016/j.bmc.2025.118178 · 2025 · External reference
Aminothiazolone inhibitors disrupt the protein–RNA interaction of METTL16 and modulate the m6A RNA modification
10.1021/jacsau.3c00832 · 2024 · External reference
STAT2/SLC27A3/PINK1-mediated mitophagy remodeling lipid metabolism contributes to pazopanib resistance in clear cell renal cell carcinoma
10.34133/research.0539 · 2024 · External reference
N6-Methyladenosine: an RNA modification as a central regulator of cancer
10.1038/s41568-025-00889-6 · 2026 · External reference
N6-methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation
10.1038/s41589-018-0184-3 · 2019 · External reference
iProX: an integrated proteome resource
10.1093/nar/gky869 · 2019 · External reference
catGRANULE 2.0: accurate predictions of liquid-liquid phase separating proteins at single amino acid resolution
10.1186/s13059-025-03497-7 · 2025 · External reference
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
10.1056/nejmoa1303989 · 2013 · External reference
IL-23 promotes PD-L1 expression and tumor immune evasion via METTL16 pathway
10.62347/ddra7133 · 2026 · External reference
Ribosome biogenesis in cancer: new players and therapeutic avenues
10.1038/nrc.2017.104 · 2018 · External reference
The U6 snRNA m6A Methyltransferase METTL16 Regulates SAM Synthetase Intron Retention
10.1016/j.cell.2017.05.003 · 2017 · External reference
Nucleolar Proteins and Non-Coding RNAs: Roles in Renal Cancer
10.3390/ijms222313126 · 2021 · External reference
Real-world effectiveness and safety of Pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma
10.1016/j.clgc.2019.01.018 · 2019 · External reference
The structure and function of small nucleolar ribonucleoproteins
10.1093/nar/gkl1172 · 2007 · External reference
Composition-dependent thermodynamics of intracellular phase separation
10.1038/s41586-020-2256-2 · 2020 · External reference
m6A enhances the phase separation potential of mRNA
10.1038/s41586-019-1374-1 · 2019 · External reference
Resistance to targeted therapy in renal-cell carcinoma
10.1016/s1470-2045(09)70240-2 · 2009 · External reference
Renal cell carcinoma: a review
10.1001/jama.2024.12848 · 2024 · External reference
Structural insights into the RNA methyltransferase domain of METTL16
10.1038/s41598-018-23608-8 · 2018 · External reference
Consequences of Binding an S -adenosylmethionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone
10.1021/bi0492556 · 2004 · External reference
Nucleolar URB1 ensures 3′ ETS rRNA removal to prevent exosome surveillance
10.1038/s41586-023-05767-5 · 2023 · External reference
RNA methyltransferase METTL16: from molecular mechanisms to therapeutic prospects in cancers
10.1016/j.canlet.2025.217698 · 2025 · External reference
The anti-angiogenic tyrosine kinase inhibitor Pazopanib kills cancer cells and disrupts endothelial networks in biomimetic three-dimensional renal tumouroids
10.1177/2041731420920597 · 2020 · External reference
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
10.1200/jco.2009.23.9764 · 2010 · External reference
Lactylation of METTL16 promotes cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer
10.1038/s41467-023-42025-8 · 2023 · External reference
SnoRNA in cancer progression, metastasis and immunotherapy response
10.3390/biology10080809 · 2021 · External reference
The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112
10.1093/nar/gkz619 · 2019 · External reference
m6A methyltransferase METTL16 mediates immune evasion of colorectal cancer cells via epigenetically regulating PD-L1 expression
10.18632/aging.204980 · 2023 · External reference
METTL16 promotes translation and lung tumorigenesis by sequestering cytoplasmic eIF4E2
2023 · External reference
Tumor-resident streptococcus pneumoniae promotes malignant progression and pazopanib resistance in clear cell renal cell carcinoma
2026 · External reference
Downregulation of UBB potentiates SP1/VEGFA-dependent angiogenesis in clear cell renal cell carcinoma
10.1038/s41388-024-03003-6 · 2024 · External reference
METTL16 promotes cell proliferation by up-regulating cyclin D1 expression in gastric cancer
10.1111/jcmm.16664 · 2021 · External reference
N6-methyladenosine Modulates Messenger RNA Translation Efficiency
10.1016/j.cell.2015.05.014 · 2015 · External reference
Hypoxia induces hepatocellular carcinoma metastasis via the HIF-1α/METTL16/lnc-CSMD1-7/RBFOX2 axis
10.1016/j.isci.2023.108495 · 2023 · External reference
Human METTL16 is a N6-methyladenosine (m6A) methyltransferase that targets pre-mRNAs and various non-coding RNAs
10.15252/embr.201744940 · 2017 · External reference
RNA modifications in gene regulation: functions and pathways
10.1016/j.cell.2026.01.006 · 2026 · External reference
METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression
10.1186/s13046-023-02732-y · 2023 · External reference
METTL16 Promotes Stability of SYNPO2L mRNA and leading to Cancer Cell Lung Metastasis by Secretion of COL10A1 and attract the Cancer-Associated Fibroblasts
10.7150/ijbs.95375 · 2024 · External reference
An Elongation- and Ligation-Based qPCR amplification method for the radiolabeling-free detection of locus-specific N6 -methyladenosine modification
10.1002/anie.201807942 · 2018 · External reference
Unraveling m6A RNA methylation: from epitranscriptomics to therapeutic frontiers in renal cell carcinoma
10.1016/j.cellsig.2025.111952 · 2025 · External reference
Multi-omics analysis reveals the role of ribosome biogenesis in malignant clear cell renal cell carcinoma and the development of a machine learning-based prognostic model
2025 · External reference
METTL16 epigenetically enhances GPX4 expression via m6A modification to promote breast cancer progression by inhibiting ferroptosis
10.1016/j.bbrc.2022.10.065 · 2023 · External reference
METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway
10.7150/ijbs.86719 · 2024 · External reference
Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A modification to suppress cholesterol metabolism and cisplatin resistance in ESCC
2026 · External reference
The GSA Family in 2025: a broadened sharing platform for multi-omics and multimodal data
2025 · External reference
PDK1 elevation was induced by epigenetic modifications of KDM3A and METTL16 to mediate TKI resistance and cancer development
2026 · External reference
Endothelial USP2a-METTL16 loop potentiates IL-6 signaling via m6A-mediated IL-6R stabilization in pulmonary vascular remodeling
2026 · External reference
Renal cell carcinoma: a review
10.1001/jama.2024.12848 · ExternalCitation · doi-reference
An Elongation- and Ligation-Based qPCR amplification method for the radiolabeling-free detection of locus-specific N6 -methyladenosine modification
10.1002/anie.201807942 · ExternalCitation · doi-reference
Renal cancer: signaling pathways and advances in targeted therapies
10.1002/mco2.676 · ExternalCitation · doi-reference
METTL16 inhibits papillary thyroid cancer tumorigenicity through m6A/YTHDC2/SCD1-regulated lipid metabolism
10.1007/s00018-024-05146-x · ExternalCitation · doi-reference
The promoting effect of the POU3F2/METTL16/PFKM cascade on glycolysis and tumorigenesis of hepatocellular carcinoma
10.1016/j.aohep.2025.101776 · ExternalCitation · doi-reference
METTL16 epigenetically enhances GPX4 expression via m6A modification to promote breast cancer progression by inhibiting ferroptosis
10.1016/j.bbrc.2022.10.065 · ExternalCitation · doi-reference
A novel cinnamic acid derivative for hepatocellular carcinoma therapy by degrading METTL16 protein
10.1016/j.bmc.2025.118178 · ExternalCitation · doi-reference
RNA methyltransferase METTL16: from molecular mechanisms to therapeutic prospects in cancers
10.1016/j.canlet.2025.217698 · ExternalCitation · doi-reference
N6-methyladenosine Modulates Messenger RNA Translation Efficiency
10.1016/j.cell.2015.05.014 · ExternalCitation · doi-reference
Coexisting Liquid Phases Underlie Nucleolar Subcompartments
10.1016/j.cell.2016.04.047 · ExternalCitation · doi-reference
The U6 snRNA m6A Methyltransferase METTL16 Regulates SAM Synthetase Intron Retention
10.1016/j.cell.2017.05.003 · ExternalCitation · doi-reference
Proteogenomic characterization of endometrial carcinoma
10.1016/j.cell.2020.01.026 · ExternalCitation · doi-reference
RNA modifications in gene regulation: functions and pathways
10.1016/j.cell.2026.01.006 · ExternalCitation · doi-reference
Unraveling m6A RNA methylation: from epitranscriptomics to therapeutic frontiers in renal cell carcinoma
10.1016/j.cellsig.2025.111952 · ExternalCitation · doi-reference
GLI2/Parkin-mediated mitophagy promotes pazopanib resistance in clear cell renal cell carcinoma
10.1016/j.cellsig.2025.112054 · ExternalCitation · doi-reference
Real-world effectiveness and safety of Pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma
10.1016/j.clgc.2019.01.018 · ExternalCitation · doi-reference
Epidemiology of renal cancer: incidence, mortality, survival, genetic predisposition, and risk factors
10.1016/j.eururo.2025.06.005 · ExternalCitation · doi-reference
Hypoxia induces hepatocellular carcinoma metastasis via the HIF-1α/METTL16/lnc-CSMD1-7/RBFOX2 axis
10.1016/j.isci.2023.108495 · ExternalCitation · doi-reference
METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism
10.1016/j.stem.2022.12.006 · ExternalCitation · doi-reference
Resistance to targeted therapy in renal-cell carcinoma
10.1016/s1470-2045(09)70240-2 · ExternalCitation · doi-reference
Methyl-transferase-like protein 16 (METTL16): the intriguing journey of a key epitranscriptomic player becoming an emerging biological target
10.1021/acs.jmedchem.4c01247 · ExternalCitation · doi-reference
Consequences of Binding an S -adenosylmethionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone
10.1021/bi0492556 · ExternalCitation · doi-reference
Aminothiazolone inhibitors disrupt the protein–RNA interaction of METTL16 and modulate the m6A RNA modification
10.1021/jacsau.3c00832 · ExternalCitation · doi-reference
Ribosome biogenesis in cancer: new players and therapeutic avenues
10.1038/nrc.2017.104 · ExternalCitation · doi-reference
Pazopanib
10.1038/nrd3073 · ExternalCitation · doi-reference
Targeting the translation machinery in cancer
10.1038/nrd4505 · ExternalCitation · doi-reference
CDK13 drives clear cell renal carcinoma through METTL16-mediated m6A modification of ACLY mRNA
10.1038/s12276-025-01634-7 · ExternalCitation · doi-reference
Downregulation of UBB potentiates SP1/VEGFA-dependent angiogenesis in clear cell renal cell carcinoma
10.1038/s41388-024-03003-6 · ExternalCitation · doi-reference
Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma
10.1038/s41420-023-01423-z · ExternalCitation · doi-reference
Lactylation of METTL16 promotes cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer
10.1038/s41467-023-42025-8 · ExternalCitation · doi-reference
N6-Methyladenosine: an RNA modification as a central regulator of cancer
10.1038/s41568-025-00889-6 · ExternalCitation · doi-reference
m6A enhances the phase separation potential of mRNA
10.1038/s41586-019-1374-1 · ExternalCitation · doi-reference
Composition-dependent thermodynamics of intracellular phase separation
10.1038/s41586-020-2256-2 · ExternalCitation · doi-reference
Nucleolar URB1 ensures 3′ ETS rRNA removal to prevent exosome surveillance
10.1038/s41586-023-05767-5 · ExternalCitation · doi-reference
N6-methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation
10.1038/s41589-018-0184-3 · ExternalCitation · doi-reference
Structural insights into the RNA methyltransferase domain of METTL16
10.1038/s41598-018-23608-8 · ExternalCitation · doi-reference
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
10.1056/nejmoa1303989 · ExternalCitation · doi-reference
iProX in 2021: connecting proteomics data sharing with big data
10.1093/nar/gkab1081 · ExternalCitation · doi-reference
Database resources of the National Genomics Data Center, China National Center for Bioinformation in 2026
10.1093/nar/gkaf1172 · ExternalCitation · doi-reference
The structure and function of small nucleolar ribonucleoproteins
10.1093/nar/gkl1172 · ExternalCitation · doi-reference
iProX: an integrated proteome resource
10.1093/nar/gky869 · ExternalCitation · doi-reference
The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112
10.1093/nar/gkz619 · ExternalCitation · doi-reference
Grading of renal cell carcinoma
10.1111/his.13735 · ExternalCitation · doi-reference
METTL16 promotes cell proliferation by up-regulating cyclin D1 expression in gastric cancer
10.1111/jcmm.16664 · ExternalCitation · doi-reference
The anti-angiogenic tyrosine kinase inhibitor Pazopanib kills cancer cells and disrupts endothelial networks in biomimetic three-dimensional renal tumouroids
10.1177/2041731420920597 · ExternalCitation · doi-reference
METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m6A-dependent manner
10.1186/s11658-022-00342-8 · ExternalCitation · doi-reference
METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression
10.1186/s13046-023-02732-y · ExternalCitation · doi-reference
catGRANULE 2.0: accurate predictions of liquid-liquid phase separating proteins at single amino acid resolution
10.1186/s13059-025-03497-7 · ExternalCitation · doi-reference
Efficacy and safety of Pazopanib in patients with metastatic renal cell carcinoma
10.1200/jco.2008.21.6994 · ExternalCitation · doi-reference
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
10.1200/jco.2009.23.9764 · ExternalCitation · doi-reference
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
10.1200/jco.2013.50.8267 · ExternalCitation · doi-reference
Human METTL16 is a N6-methyladenosine (m6A) methyltransferase that targets pre-mRNAs and various non-coding RNAs
10.15252/embr.201744940 · ExternalCitation · doi-reference
m6A methyltransferase METTL16 mediates immune evasion of colorectal cancer cells via epigenetically regulating PD-L1 expression
10.18632/aging.204980 · ExternalCitation · doi-reference
SnoRNA in cancer progression, metastasis and immunotherapy response
10.3390/biology10080809 · ExternalCitation · doi-reference
Emerging role of eukaryote ribosomes in translational control
10.3390/ijms20051226 · ExternalCitation · doi-reference
Nucleolar Proteins and Non-Coding RNAs: Roles in Renal Cancer
10.3390/ijms222313126 · ExternalCitation · doi-reference
Metabolomics reveals tyrosine kinase inhibitor resistance-associated metabolic events in human metastatic renal cancer cells
10.3390/ijms25126328 · ExternalCitation · doi-reference
STAT2/SLC27A3/PINK1-mediated mitophagy remodeling lipid metabolism contributes to pazopanib resistance in clear cell renal cell carcinoma
10.34133/research.0539 · ExternalCitation · doi-reference
IL-23 promotes PD-L1 expression and tumor immune evasion via METTL16 pathway
10.62347/ddra7133 · ExternalCitation · doi-reference
METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway
10.7150/ijbs.86719 · ExternalCitation · doi-reference
METTL16 Promotes Stability of SYNPO2L mRNA and leading to Cancer Cell Lung Metastasis by Secretion of COL10A1 and attract the Cancer-Associated Fibroblasts
10.7150/ijbs.95375 · ExternalCitation · doi-reference
